Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
There has been no change, the sites you have mentioned that are reporting the fall are simply showing the last trade price as the difference from yesterday's close. SP remains at .04/.09p.
Moving north again! 13.3% up, looks like news is just around the corner, great rise! GLA
Some large buys again today! I would imagine we will see another holdings RNS very soon! News shouldn't be long now. GLA
Rangers! Should help bring in larger clubs. GLS
When we get an update, this share is very news driven. However when news is released if it is good then you will find it very hard to buy anywhere near the current level IMHO. Will be full ask and more. GL
2.1M buy on PLUS @ .07p. Update soon hopefully... GLA
The global biomarker market is estimated to be $20.5 billion by 2014, growing at a CAGR of 19.7 % from 2009 to 2014, driven by the high demand for the biomarkers in the field of drug discovery. The markets for biomarker tools and services are expected to grow at a CAGR of 18.5% and 22.2% respectively. The increasing use of biomarkers in clinical services is boosting the overall biomarker service market. The high growth of biomarker market is boosted by the demand from the baby boomer generation in the U.S., and from Asia's emerging IT industry. Biomarker applications are increasing in cancer diagnosis as novel tools are being developed to increase the discovery speed of cancer biomarkers. The use of proteomics in biomarker testing and identification has in turn boosted the services for the biomarkers. Market players are now focusing on new product and service development to enhance their commercial portfolios. Strategic collaborations among companies are also increasing biomarker applications in the field of diagnosis and drug discovery. http://www.articlesbase.com/business-ideas-articles/marketsandmarkets-global-biomarker-market-worth-us-205-billion-by-2014-3116462.html
No need to apologise, was just curious as to why you posted exactly the same message on 3 bb's without any insight! Another collaboration within the industry: Clearstone partners to boost biomarkers, esoteric services By Nick Taylor, 19-Aug-2010 Related topics: Globalisation, Clinical evolution, Clinical Development, Analytical testing, QC Clearstone Central Laboratories is partnering with LabCorp to give clients access to more biomarker and esoteric services. Partnering with Laboratory Corporation of America (LabCorp) gives Clearstone access to an array of speciality capabilities. Also, combining LabCorp’s expertise in North America with Clearstone’s global network expands the geographic reach both organisations can offer clients. Lewis Cameron, CEO of Clearstone, told Outsourcing-Pharma: “LabCorp’s expertise in North America and impressive biomarker and esoteric capabilities offers clients something really compelling to evaluate for their upcoming clinical studies. “As sponsors pare back the number of outsourcing relationships they wish to maintain, a need has arisen for central labs to offer a truly global footprint with scientific expertise in a broad range of testing, from higher volume safety testing to biomarker and other more esoteric testing.” Partnering could also help Clearstone build its in-house capabilities. LabCorp and Clearstone will “work together to grow and cultivate expertise and scientific capabilities in strategic regions”, said Cameron. The lab in Beijing, China was highlighted as one such “strategic region”. Clients will be able to assess the range of capabilities at both companies before deciding to outsource to one or both. Business development teams will remain distinct but clients can choose to work with a single point of contact. Each partner will earn revenues for the work they perform. Opportunities The customer bases of both companies are quite different, said Cameron, creating “many exciting opportunities”. Clearstone and LabCorp have already begun the collaboration and will develop and refine aspects of it in response to the needs of clients. Cameron said: “We have been delighted by the positive response to the collaboration already. The one-stop, best-of-breed nature of the collaboration seems to have struck a chord with many current and potential clients.” Terms of the collaboration have not been disclosed. However, David Johnston, vice president and global head, clinical trials at LabCorp, told Outsourcing-Pharma: “We are all coming to this with a view that the collaboration will be long term and lasting.” http://www.outsourcing-pharma.com/Clinical-Development/Clearstone-partners-to-boost-biomarkers-esoteric-services Are we going to be next?
Great news, Credit Agricole have been accumulating stock as well. News soon ;) GLA
For anyone that hasn't seen this yet: http://www.proteome.re.kr/data/?kind=1&subKind=1&boardPage=1&mod=view&idx=522&searchKind=title&searchTxt=nextgen
Why have you put the exact same message on 3 boards? Do you not have a view or a specific question regarding the share? How is this going belly up? It has actually risen in the last couple of days a touch and then fallen back a little... the next bit of news i am expecting is the certification they are awaiting. Any further collaboration or contract win in the mean time will be a great bonus and can see a good mark up on the back of any good news. GL
Hello mate, good to hear from you. Yes still have an interest in pharma's. Have a few on the watchlist but invested in here. Glad NPH served you well in the end, unfortunately i had no such luck! Held on hoping for a better outcome. Huge lesson learnt there... something that looks a sure thing doesn't always come off. Wish i had topsliced a few near 40p but there we go! Thanks for the tip on PPC, i will check it out. If your into you oil & gas co.s you may want to have a little gander at IRG, i am in quite large as can see a great year ahead of them, due to drill soon as well. Hope all is well. ATB
Another 1mill buy just in, after a couple more 1mill buys and a 500k buy on Friday it looks as if the stakebuilder is still out there. Bodes well...
was a sharp tick back up!
629k buy first thing @ .081p, be nice to see a tick up today! GLA
More money being spent in the industry: http://www.genomeweb.com//node/947296?hq_e=el&hq_m=786283&hq_l=2&hq_v=7d12dee5b6
The pharmaceutical and biotechnology industry is under pressure to reduce the attrition rate of compounds through the development process. The industry is looking towards biomarkers and better target selection as the best means of improving the attrition rate. Industry and its regulators see these as key solutions to the drug development problem especially as related to efficacy and safety. So much so, that the use of molecular biomarkers is becoming mandatory for drug development programs. The role of biomarkers spans all aspects of drug discovery and development. It has been recognized that integration of biomarkers through the different phases of drug development can yield safer drugs with enhanced therapeutic efficacy in a cost-effective manner. Biomarkers also provide the critical link in translational medicine (bench to bedside) and are essential for the realization of personalized medicine.'
of small buy this morning, hope to see a few more and a further tick up here, certification news soon hopefully :)
2mill buy at full ask on the bell! Good to see, hopefully another good day tomorrow. GL